The compatibility of biosimilar filgrastim under cytotoxic chemotherapy in the treatment of malignant diseases: VENICE study

被引：0
|
作者：
Otremba, B. [1 ]
Salat, C. [2 ]
Stoetzer, O. [2 ]
Kittel, K. [3 ]
Maucksch, C. [4 ]
机构：
[1] Standort Oldenburg, Onkol Praxis Oldenburg Delmenhorst, Oldenburg, Germany
[2] Praxis M unchen, Hamato Onkol Schwerpunktpraxis, Munich, Germany
[3] Standort Lichtenberg, Praxisklin Brustzentrum, Berlin, Germany
[4] Hosp Deutschland GmbH, Med Affairs, Munich, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30659-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1570
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [1] Prophylactic Biosimilar Filgrastim Treatment during Cytotoxic Chemotherapy in Patients with Malignant Diseases: The Venice Observational Study
    Otremba, Burkhard
    Erdlenbruch, Wolfhard
    BLOOD, 2015, 126 (23)
  • [2] Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
    Fruehauf, Stefan
    Otremba, Burkhard
    Stoetzer, Oliver
    Rudolph, Christine
    ADVANCES IN THERAPY, 2016, 33 (11) : 1983 - 2000
  • [3] Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
    Stefan Fruehauf
    Burkhard Otremba
    Oliver Stötzer
    Christine Rudolph
    Advances in Therapy, 2016, 33 : 1983 - 2000
  • [4] Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma
    Shimano, Rena
    Yamamoto, Hisashi
    Nasu, Izumi
    Kashiwamura, Yuichiro
    Yamamoto, Go
    Uchida, Naoyuki
    Taniguchi, Shuichi
    Hayashi, Masahiro
    Ito, Tadaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 856 - 862
  • [5] Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma
    Rena Shimano
    Hisashi Yamamoto
    Izumi Nasu
    Yuichiro Kashiwamura
    Go Yamamoto
    Naoyuki Uchida
    Shuichi Taniguchi
    Masahiro Hayashi
    Tadaaki Ito
    International Journal of Hematology, 2022, 116 : 856 - 862
  • [6] NEXT and VENICE: design of two multicentre, phase IV, prospective, longitudinal studies evaluating the safety profile of a biosimilar filgrastim in patients treated with cytotoxic chemotherapy
    Fruehauf, S.
    Berthou, C.
    Lepretre, S.
    Cals, L.
    Maloisel, F.
    Kamioner, D.
    ONKOLOGIE, 2012, 35 : 72 - 72
  • [7] NEXT AND VENICE: DESIGN OF TWO MULTICENTRE, PHASE IV, PROSPECTIVE, LONGITUDINAL STUDIES EVALUATING THE SAFETY PROFILE OF A BIOSIMILAR FILGRASTIM IN PATIENTS TREATED WITH CYTOTOXIC CHEMOTHERAPY
    Fruehauf, S.
    Berthou, C.
    Lepretre, S.
    Cals, L.
    Maloisel, F.
    Kamioner, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 522 - 522
  • [8] Supportive Treatment of Chemotherapy-Induced Neutropenia With Biosimilar Filgrastim: the HEXAFIL Non-Interventional Study
    Tesch, H.
    Indorf, M.
    Schaller-Kranz, T.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S280 - S281
  • [9] Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
    Sevinc, Alper
    Ozkan, Metin
    Ozet, Ahmet
    Dane, Faysal
    Oksuzoglu, Berna
    Isikdogan, Abdurrahman
    Ozdemir, Feyyaz
    Uncu, Dogan
    Gumus, Mahmut
    Evrensel, Turkkan
    Yaren, Arzu
    Kara, Oguz
    Tekin, Salim Basol
    ONCOTARGETS AND THERAPY, 2018, 11 : 419 - 426
  • [10] Biosimilar filgrastim in the treatment of patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study
    Albrand, H.
    Kamioner, D.
    Lepretre, S.
    CANCER RESEARCH, 2016, 76
12345